AZP-531: Interim Phase I data

Interim data from a 3-part, double-blind, placebo-controlled, U.K. Phase Ia/Ib trial showed that subcutaneous AZP-531 was well tolerated as single ascending doses in 44 healthy volunteers and as once-...